

Ian F Parney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7038404/publications.pdf>

Version: 2024-02-01

161
papers

10,494
citations

31976

53
h-index

34986

98
g-index

162
all docs

162
docs citations

162
times ranked

13885
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma. <i>Journal of Neurosurgery</i> , 2022, 136, 30-39.	1.6	2
2	Pediatric brain tumor cell lines exhibit miRNA-depleted, Y RNA-enriched extracellular vesicles. <i>Journal of Neuro-Oncology</i> , 2022, 156, 269-279.	2.9	7
3	Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN- γ through PD-L1 and IDO1. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	8
4	Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. <i>Molecular Cancer Research</i> , 2022, 20, 938-948.	3.4	22
5	Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI). <i>Journal of Neuro-Oncology</i> , 2022, 158, 349-357.	2.9	10
6	Letter: The Morbidity and Mortality of Surgery for Traumatic Brain Injury in Geriatric Patients: A Study of Over 100 000 Patient Cases. <i>Neurosurgery</i> , 2022, Publish Ahead of Print, .	1.1	1
7	Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	6
8	Multiparametric analysis in GBM plasma extracellular vesicles (Evs) and surface marker expression profile.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2038-2038.	1.6	0
9	Higher temporal resolution multiband fMRI provides improved presurgical language maps. <i>Neuroradiology</i> , 2021, 63, 439-445.	2.2	4
10	Journal of Neuro Oncology: immunotherapy for brain tumors. <i>Journal of Neuro-Oncology</i> , 2021, 151, 1-1.	2.9	2
11	Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. <i>Clinical and Translational Immunology</i> , 2021, 10, e1267.	3.8	4
12	Salvage Radiosurgery for Recurrent Supratentorial Primitive Neuroectodermal Tumors: A Single Institutional Series and Review of the Literature. <i>Stereotactic and Functional Neurosurgery</i> , 2021, 99, 405-411.	1.5	0
13	Neurosurgical involvement in clinical trials for CNS tumors. <i>Journal of Neuro-Oncology</i> , 2021, 151, 367-373.	2.9	1
14	Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 2042-2053.	1.2	37
15	Plasma extracellular vesicles as a source of biomarkers in traumatic brain injury. <i>Journal of Neurosurgery</i> , 2021, 134, 1921-1928.	1.6	13
16	Carbon Fiducial Markers for Tumor Localization in Stereotactic Irradiation of Uveal Melanoma. <i>Ocular Oncology and Pathology</i> , 2021, 7, 368-375.	1.0	3
17	The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience. <i>Journal of Neuro-Oncology</i> , 2021, 155, 335-342.	2.9	7
18	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 770561.	2.8	51

#	ARTICLE	IF	CITATIONS
19	A Review on the Surgical Management of Insular Gliomas. Canadian Journal of Neurological Sciences, 2021, , 1-26.	0.5	0
20	Long-Term Control after Radiosurgery for a Recurrent Supratentorial Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature. Stereotactic and Functional Neurosurgery, 2021, 99, 267-269.	1.5	1
21	Does the dural resection bed need to be irradiated? Patterns of recurrence and implications for postoperative radiotherapy for temporal lobe gliomas. Neuro-Oncology Practice, 2021, 8, 190-198.	1.6	1
22	Disparities in access to surgery for glioblastoma multiforme at high-volume Commission on Cancer“accredited hospitals in the United States. Journal of Neurosurgery, 2021, , 1-10.	1.6	2
23	Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma. Journal of Neurosurgery, 2020, 133, 1637-1645.	1.6	20
24	Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). International Journal of Radiation Oncology Biology Physics, 2020, 106, 255-260.	0.8	22
25	Short non-coding RNA sequencing of glioblastoma extracellular vesicles. Journal of Neuro-Oncology, 2020, 146, 253-263.	2.9	20
26	Anti“PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro-Oncology, 2020, 22, 639-651.	1.2	34
27	Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa105.	0.7	8
28	In Reply to the Letter to the Editor Regarding “A Surprise Sabbatical: How Mayo Clinic Neurosurgery Coped with COVID-19“ World Neurosurgery, 2020, 144, 330.	1.3	0
29	Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. Brain, 2020, 143, 3629-3652.	7.6	41
30	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	1.2	1
31	Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry. Journal of Neuro-Oncology, 2020, 149, 293-303.	2.9	7
32	Letter to the Editor: Survey of Academic U.S. Programs Regarding the Impact of the COVID-19 Pandemic on Clinical Practice, Education, and Research in Neurosurgery. World Neurosurgery, 2020, 140, 476-478.	1.3	5
33	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro-Oncology, 2020, 22, 757-772.	1.2	131
34	Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series. Canadian Journal of Neurological Sciences, 2020, 47, 525-530.	0.5	10
35	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Neuro-Oncology, 2020, 22, 967-978.	1.2	62
36	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clinical Cancer Research, 2020, 26, 1094-1104.	7.0	124

#	ARTICLE	IF	CITATIONS
37	Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 341-352.	3.3	15
38	Venous thromboembolic events in patients undergoing craniotomy for tumor resection: incidence, predictors, and review of literature. <i>Journal of Neurosurgery</i> , 2020, 132, 10-21.	1.6	30
39	Risk of internal carotid artery stenosis or occlusion after single-fraction radiosurgery for benign parasellar tumors. <i>Journal of Neurosurgery</i> , 2020, 133, 1388-1395.	1.6	9
40	Morbidity and mortality in elderly patients undergoing evacuation of acute traumatic subdural hematoma. <i>Neurosurgical Focus</i> , 2020, 49, E22.	2.3	22
41	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1537-1570.	4.9	253
42	Introduction. Cranial surgery in geriatric patients. <i>Neurosurgical Focus</i> , 2020, 49, E1.	2.3	1
43	Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery: A Systematic Review and Meta-analysis. <i>Neurosurgery</i> , 2019, 84, 569-580.	1.1	30
44	Isolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma. <i>Frontiers in Oncology</i> , 2019, 9, 651.	2.8	68
45	Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells. <i>PLoS ONE</i> , 2019, 14, e0220569.	2.5	15
46	Cerebral blood volume and apparent diffusion coefficient – Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116433.	0.6	14
47	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	2.8	32
48	The T2-FLAIR mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. <i>Neurosurgical Focus</i> , 2019, 47, E13.	2.3	30
49	MR Elastography Analysis of Glioma Stiffness and IDH1-Mutation Status. <i>American Journal of Neuroradiology</i> , 2018, 39, 31-36.	2.4	70
50	Cranial Tumor Surgical Outcomes at a High-Volume Academic Referral Center. <i>Mayo Clinic Proceedings</i> , 2018, 93, 16-24.	3.0	11
51	Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. <i>World Neurosurgery</i> , 2018, 110, 276-283.	1.3	38
52	Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 583-591.	2.9	26
53	Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. <i>Brain Pathology</i> , 2018, 28, 172-182.	4.1	64
54	Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. <i>Neuro-Oncology</i> , 2018, 20, 184-191.	1.2	443

#	ARTICLE	IF	CITATIONS
55	Preoperative Stereotactic Radiosurgery for Brain Metastases. <i>Frontiers in Neurology</i> , 2018, 9, 959.	2.4	41
56	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	6.3	83
57	Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1893-1901.	4.1	37
58	The reliability of YouTube videos in patients education for Glioblastoma Treatment. <i>Journal of Clinical Neuroscience</i> , 2018, 55, 1-4.	1.5	67
59	A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. <i>Nature Communications</i> , 2018, 9, 2949.	12.8	183
60	Insurance correlates with improved access to care and outcome among glioblastoma patients. <i>Neuro-Oncology</i> , 2018, 20, 1374-1382.	1.2	34
61	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. <i>American Journal of Neuroradiology</i> , 2017, 38, 678-684.	2.4	63
62	The Risk of Radiation-Induced Tumors or Malignant Transformation After Single-Fraction Intracranial Radiosurgery: Results Based on a 25-Year Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 919-923.	0.8	70
63	Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience. <i>Journal of Neuro-Oncology</i> , 2017, 133, 339-346.	2.9	14
64	Management of diffuse low-grade gliomas in adults – use of molecular diagnostics. <i>Nature Reviews Neurology</i> , 2017, 13, 340-351.	10.1	95
65	Residual Deep Convolutional Neural Network Predicts MGMT Methylation Status. <i>Journal of Digital Imaging</i> , 2017, 30, 622-628.	2.9	152
66	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1331-1345.	4.9	160
67	Gamma Knife Stereotactic Radiosurgery for the Treatment of Primary and Metastatic Ocular Malignancies. <i>Stereotactic and Functional Neurosurgery</i> , 2017, 95, 363-368.	1.5	14
68	Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence. <i>Journal of Digital Imaging</i> , 2017, 30, 469-476.	2.9	167
69	Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1049-1060.	10.7	840
70	Nested Cohort Study to Identify Characteristics That Predict Near-Term Disablement From Lung Cancer Brain Metastases. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 303-311.e1.	0.9	6
71	ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi29-vi29.	1.2	21
72	Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. <i>PLoS ONE</i> , 2017, 12, e0179012.	2.5	60

#	ARTICLE	IF	CITATIONS
73	Commentary. Operative Neurosurgery, 2016, 12, 339.	0.8	0
74	Carbon fiducials for large choroidal melanoma treated with gamma knife radiosurgery. Acta Ophthalmologica, 2016, 94, e806-e807.	1.1	3
75	MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Medical Physics, 2016, 43, 2835-2844.	3.0	142
76	336â€fSmall RNA Sequencing of Glioblastoma Multiforme Extracellular Vesicles. Neurosurgery, 2016, 63, 198.	1.1	8
77	Predictors of Surgical Site Infection Following Craniotomy for Intracranial Neoplasms: An Analysis of Prospectively Collected Data in the American College of Surgeons National Surgical Quality Improvement Program Database. World Neurosurgery, 2016, 88, 350-358.	1.3	62
78	Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics, 2016, 13, 226-236.	4.4	24
79	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-Oncology, 2016, 18, 518-527.	1.2	57
80	Central Nervous System Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1191-1202.	4.9	89
81	Dexmedetomidine and Mannitol for Awake Craniotomy in a Pregnant Patient. Anesthesia and Analgesia, 2015, 120, 1099-1103.	2.2	22
82	Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. PLoS ONE, 2015, 10, e0125565.	2.5	22
83	Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression. Journal of Medical Imaging, 2015, 2, 026001.	1.5	20
84	Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro-Oncology, 2015, 17, 978-991.	1.2	80
85	Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration. Medical Hypotheses, 2015, 85, 127-129.	1.5	6
86	Stereotactic Radiosurgery in the Treatment of Recurrent CNS Lymphoma. World Neurosurgery, 2015, 84, 390-397.	1.3	16
87	Using comprehensive immune profiles to identify glioblastoma patients responsive to autologous dendritic cell vaccines. Cytotherapy, 2015, 17, S17.	0.7	0
88	The role of radiotherapy in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 551-583.	2.9	50
89	Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor. Journal of Neuro-Oncology, 2014, 120, 371-379.	2.9	15
90	Long-term Outcomes and Role of Chemotherapy in Adults With Newly Diagnosed Medulloblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 1-7.	1.3	22

#	ARTICLE	IF	CITATIONS
91	Clinical trials in neurosurgical oncology. <i>Journal of Neuro-Oncology</i> , 2014, 119, 569-576.	2.9	4
92	The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014, 120, 85-93.	2.9	30
93	Focal Encephalitis Following Varicella-Zoster Virus Reactivation Without Rash in a Healthy Immunized Young Adult. <i>Journal of Infectious Diseases</i> , 2014, 210, 713-716.	4.0	24
94	Immune Response: Glioma-Associated Immunosuppression. , 2014, , 221-239.		2
95	Gliomatosis cerebri: clinical characteristics, management, and outcomes. <i>Journal of Neuro-Oncology</i> , 2013, 112, 267-275.	2.9	61
96	Surgical outcomes in recurrent glioma. <i>Journal of Neurosurgery</i> , 2013, 118, 1224-1231.	1.6	57
97	Association between the Cerebral Inflammatory and Matrix Metalloproteinase Responses after Severe Traumatic Brain Injury in Humans. <i>Journal of Neurotrauma</i> , 2013, 30, 1727-1736.	3.4	48
98	A Prospective Evaluation of the Temporal Matrix Metalloproteinase Response after Severe Traumatic Brain Injury in Humans. <i>Journal of Neurotrauma</i> , 2013, 30, 1717-1726.	3.4	33
99	The role of LAT1 in 18F-DOPA uptake in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 111, 11-18.	2.9	123
100	Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. <i>Journal of Neurosurgery</i> , 2013, 118, 786-798.	1.6	92
101	Brain carcinoid metastases: outcomes and prognostic factors. <i>Journal of Neurosurgery</i> , 2013, 118, 889-895.	1.6	28
102	Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years. <i>Neuro-Oncology</i> , 2013, 15, 1102-1110.	1.2	49
103	Editorial: Glioblastoma in the elderly. <i>Journal of Neurosurgery</i> , 2013, 118, 783-785.	1.6	9
104	Adult Low-grade Glioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 612-619.	1.3	43
105	Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. <i>Neuro-Oncology</i> , 2013, 15, 1058-1067.	1.2	163
106	The NF- κ B RelB Protein Is an Oncogenic Driver of Mesenchymal Glioma. <i>PLoS ONE</i> , 2013, 8, e57489.	2.5	52
107	Principles of brain tumor surgery. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 187-213.	1.8	14
108	Increased Frameless Stereotactic Accuracy With High-Field Intraoperative Magnetic Resonance Imaging. <i>Operative Neurosurgery</i> , 2012, 71, ons321-ons328.	0.8	6

#	ARTICLE	IF	CITATIONS
109	Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2012, 110, 227-235.	2.9	14
110	Radiosurgery to the Postoperative Surgical Cavity: Who Needs Evidence?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 486-493.	0.8	74
111	In Reply to Prabhu et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 569-570.	0.8	0
112	Basic Concepts in Glioma Immunology. <i>Advances in Experimental Medicine and Biology</i> , 2012, 746, 42-52.	1.6	44
113	Use of Movable High-Field-Strength Intraoperative Magnetic Resonance Imaging With Awake Craniotomies for Resection of Gliomas: Preliminary Experience. <i>Neurosurgery</i> , 2011, 69, 194-206.	1.1	56
114	Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 102, 255-260.	2.9	47
115	Oxygen Is a Master Regulator of the Immunogenicity of Primary Human Glioma Cells. <i>Cancer Research</i> , 2011, 71, 6583-6589.	0.9	20
116	Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. <i>Journal of Neuro-Oncology</i> , 2010, 96, 403-408.	2.9	47
117	Awake Craniotomy, Electrophysiologic Mapping, and Tumor Resection With High-Field Intraoperative MRI. <i>World Neurosurgery</i> , 2010, 73, 547-551.	1.3	33
118	Oligodendroglioma cell lines containing t(1;19)(q10;p10). <i>Neuro-Oncology</i> , 2010, 12, 745-755.	1.2	77
119	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. <i>Neuro-Oncology</i> , 2010, 12, 351-365.	1.2	197
120	Clinical Trials in Brain Tumor Surgery. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 409-424.	1.0	9
121	Flow cytometry and in vitro analysis of human glioma-associated macrophages. <i>Journal of Neurosurgery</i> , 2009, 110, 572-582.	1.6	150
122	Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens. <i>Stem Cells</i> , 2009, 27, 1722-1733.	3.2	175
123	Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM. <i>Canadian Journal of Neurological Sciences</i> , 2009, 36, 617-622.	0.5	62
124	MULTIFOCAL COMPLEX GLIONEURONAL TUMOR IN AN ELDERLY MAN. <i>Neurosurgery</i> , 2009, 64, E1193-E1195.	1.1	21
125	Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2008, 89, 97-103.	2.9	128
126	The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma. <i>Clinical Cancer Research</i> , 2008, 14, 2357-2362.	7.0	109

#	ARTICLE	IF	CITATIONS
127	Leptomeningeal Disease from Oligodendroglioma: Clinical and Molecular Analysis. Canadian Journal of Neurological Sciences, 2008, 35, 204-209.	0.5	7
128	The p75 Neurotrophin Receptor Is a Central Regulator of Glioma Invasion. PLoS Biology, 2007, 5, e212.	5.6	150
129	Treatment for posterior fossa dissemination of primary supratentorial glioma. Journal of Neurosurgery, 2007, 106, 567-574.	1.6	4
130	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 2007, 13, 84-88.	30.7	1,177
131	Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. Acta Neurologica Scandinavica, 2007, 116, 259-262.	2.1	20
132	Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions?. Human Pathology, 2006, 37, 272-282.	2.0	47
133	Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. Journal of Neuro-Oncology, 2006, 78, 71-80.	2.9	39
134	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV Î”M51) on Multifocal and Invasive Gliomas. Journal of the National Cancer Institute, 2006, 98, 1546-1557.	6.3	88
135	Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13Î”PE38QQR for recurrent malignant glioma. Journal of Neurosurgery, 2005, 102, 267-275.	1.6	87
136	Patterns of Care for Adults With Newly Diagnosed Malignant Glioma. JAMA - Journal of the American Medical Association, 2005, 293, 557.	7.4	316
137	Chemotherapy Principles. , 2005, , 75-79.		1
138	Intrinsic Posterior Fossa Brain Tumors. , 2005, , 875-891.		0
139	Myxopapillary Ependymomas. , 2005, , 493-496.		0
140	Glioblastoma Multiforme. , 2005, , 143-148.		1
141	Spinal Cord and Intradural-Extraparenchymal Spinal Tumors: Current Best Care Practices and Strategies. Journal of Neuro-Oncology, 2004, 69, 291-318.	2.9	132
142	Progress in Malignant Glioma. Journal of Neurosurgery, 2004, 100, 1132-3; author reply 1133.	1.6	4
143	Cancer immunogene therapy: A review. Journal of Biomedical Science, 2003, 10, 37-43.	7.0	16
144	Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. Journal of Neurosurgery, 2003, 99, 467-473.	1.6	571

#	ARTICLE	IF	CITATIONS
145	Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. <i>Journal of Neurosurgery</i> , 2003, 98, 1175-1181.	1.6	259
146	Current Chemotherapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 149-156.	2.0	80
147	Human Brain Tumor Cell Culture Characterization after Immunostimulatory Gene Transfer. <i>Neurosurgery</i> , 2002, 50, 1094-1102.	1.1	5
148	Human Brain Tumor Cell Culture Characterization after Immunostimulatory Gene Transfer. <i>Neurosurgery</i> , 2002, 50, 1094-1102.	1.1	5
149	Human Autologous In Vitro Models of Glioma Immunogene Therapy Using B7-2, GM-CSF, and IL12. <i>Canadian Journal of Neurological Sciences</i> , 2002, 29, 267-275.	0.5	15
150	Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. <i>Acta Neuropathologica</i> , 2002, 103, 171-178.	7.7	160
151	Howard H. Hepburn and the Development of Skull Tongs for Cervical Spine Traction. <i>Neurosurgery</i> , 2000, 47, 1430-1433.	1.1	4
152	Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF. <i>Journal of Neuro-Oncology</i> , 2000, 47, 23-30.	2.9	5
153	Human Glioma Immunobiology in Vitro: Implications for Immunogene Therapy. <i>Neurosurgery</i> , 2000, 46, 1169-1178.	1.1	84
154	Glioma Immunology and Immunotherapy. <i>Neurosurgery</i> , 2000, 46, 778-792.	1.1	118
155	Heparin-induced thrombocytopenia and thrombosis following subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2000, 93, 136-139.	1.6	16
156	Glioma Immunology and Immunotherapy. <i>Neurosurgery</i> , 2000, 46, 778-792.	1.1	89
157	Antisense preendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 1999, 90, 1105-1114.	1.6	44
158	Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. <i>British Journal of Cancer</i> , 1999, 81, 638-646.	6.4	97
159	Improved technique for establishing short term human brain tumor cultures. <i>Journal of Neuro-Oncology</i> , 1999, 43, 1-10.	2.9	23
160	Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse—Human Glioblastoma Multiforme Model. <i>Human Gene Therapy</i> , 1997, 8, 1073-1085.	2.7	66
161	Idiopathic Cranial Hypertrophic Pachymeningitis Responsive to Antituberculous Therapy: Case Report. <i>Neurosurgery</i> , 1997, 41, 965-971.	1.1	78